Overexpression of EZH2 in Multiple Myeloma Is Associated with Poor Prognosis Regardless of Treatment with Novel Agents or High-Dose Chemotherapy

被引：0
|
作者：
Schroeder, Mark A.
Fiala, Mark A.
Ghobadi, Armin
Stockerl-Goldstein, Keith E.
Wildes, Tanya M.
Vij, Ravi
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4335
引用
收藏
页数：2
相关论文
共 50 条
  • [31] EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms
    Goldsmith, Scott R.
    Fiala, Mark A.
    O'Neal, Julie
    Souroullas, George P.
    Toama, Wael
    Vij, Ravi
    Schroeder, Mark A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (11): : 744 - 750
  • [32] TREATMENT OF POOR PROGNOSIS NONSEMINOMATOUS TESTICULAR CANCER WITH A HIGH-DOSE PLATINUM COMBINATION CHEMOTHERAPY REGIMEN
    OZOLS, RF
    DEISSEROTH, AB
    JAVADPOUR, N
    BARLOCK, A
    MESSERSCHMIDT, GL
    YOUNG, RC
    CANCER, 1983, 51 (10) : 1803 - 1807
  • [33] High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma
    Maisnar, V.
    Hajek, R.
    Scudla, V.
    Gregora, E.
    Buchler, T.
    Tichy, M.
    Kotoucek, P.
    Kafkova, A.
    Forraiova, L.
    Minarik, J.
    Radocha, J.
    Blaha, V.
    Maly, J.
    BONE MARROW TRANSPLANTATION, 2008, 41 (01) : 51 - 54
  • [34] High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma
    V Maisnar
    R Hájek
    V Ščudla
    E Gregora
    T Büchler
    M Tichý
    P Kotouček
    A Kafková
    L Forraiová
    J Minařík
    J Radocha
    V Bláha
    J Malý
    Bone Marrow Transplantation, 2008, 41 : 51 - 54
  • [35] Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) is associated with cancer metastasis and poor prognosis in breast cancer
    Guo, Yawen
    Maimaiti, Yusufu
    Yu, Pan
    Liu, Zeming
    Chen, Chen
    Zhang, Yunke
    Yin, Xingjie
    Wang, Shan
    Xiu, Nie
    Bangxing, Huang
    Liu, Chunping
    Huang, Tao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 2672 - 2683
  • [36] MULTIPLE-MYELOMA - COMPLETE REMISSION WITH HIGH-DOSE MELPHALAN CHEMOTHERAPY
    RICHARDS, F
    COLEMAN, M
    COOPER, MR
    BALLARD, WP
    CANCER INVESTIGATION, 1985, 3 (01) : 15 - 21
  • [37] Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy
    Biran, Noa
    Sehgal, Priya
    Sahni, Gagan
    Doucette, John
    Chari, Ajai
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : E125 - E127
  • [38] Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
    Gillich, Cedric
    Akhoundova, Dilara
    Hayoz, Michael
    Aebi, Yolanda
    Largiader, Carlo R.
    Seipel, Katja
    Daskalakis, Michael
    Bacher, Ulrike
    Pabst, Thomas
    CANCERS, 2023, 15 (10)
  • [39] Increased EZH2 Expression is Associated With Proliferation and Progression of Cervical Cancer and Indicates a Poor Prognosis
    Liu, Yueyang
    Liu, Ting
    Bao, Xiangxiang
    He, Miaolong
    Li, Ling
    Yang, Xingsheng
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2014, 33 (03) : 218 - 224
  • [40] Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma
    Desikan, R
    Veksler, Y
    Raza, S
    Stokes, B
    Sabir, T
    Li, ZJ
    Jagannath, S
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) : 496 - 499
12345